Substance / Medication

Rifapentine

Overview

Active Ingredient
rifapentine
RxNorm CUI
35617
Labeler: sanofi-aventis U.S. LLCUpdated: 2026-02-06T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
2
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Lai Wendy A, Brethour Kaitlyn, D'Silva Olivia et al. · BMC Public Health · 2022
PMID: 36476206Meta-AnalysisFull text (PMC)
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
Hibma Jennifer E, Radtke Kendra K, Dorman Susan E et al. · Am J Respir Crit Care Med · 2020
PMID: 32412342Meta-AnalysisFull text (PMC)
Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
Hamada Y, Ford N, Schenkel K et al. · Int J Tuberc Lung Dis · 2018
PMID: 30606313Meta-Analysis
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
Njie Gibril J, Morris Sapna Bamrah, Woodruff Rachel Yelk et al. · Am J Prev Med · 2018
PMID: 29910114Meta-AnalysisFull text (PMC)
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma Surendra K, Sharma Anju, Kadhiravan Tamilarasu et al. · Cochrane Database Syst Rev · 2013
PMID: 23828580Meta-AnalysisFull text (PMC)
Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review.
Gao X-F, Li J, Yang Z-W et al. · Int J Tuberc Lung Dis · 2009
PMID: 19555529Meta-Analysis
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.
Kurbatova Ekaterina V, Whitworth William C, Peddareddy Lakshmi Praveena et al. · Emerg Infect Dis · 2025
PMID: 40023788RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rifapentine (substance)
SNOMED CT
108686006
UMLS CUI
C0073372
RxNorm CUI
35617
Labeler
sanofi-aventis U.S. LLC

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.